# Amphista Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amphista-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.amphista.com
- Total disclosed funding: $54M
- Latest round: Series B (Dec 12, 2022)
- Investors on record: 9

## About

Founded in 2017 as a spin-out from Advent Life Sciences, founded by Alessio Ciulli, and based in Cambridge, UK, Amphista Therapeutics Limited operates as a biotechnology company that develops drugs and pharmaceuticals using targeted protein degradation (TPD). In December 2022, Amphista Therapeutics Limited raised GBP 7.37 million in Series B funding from SV Health Investors. The series B funding values Amphista Therapeutics Limited at GBP 86.57 million post-money. As of 2024, the company is led by its CEO, Nicola Thompson. 

Advent Life Sciences offers Proprietary EclipsysTM, a drug development platform for identifying new TPD mechanisms and optimizing bifunctional TPD therapies. The company’s platform targets a broad range of diseases in oncology, immunology, CNS disorders, and other areas capable of degrading proteins, including nuclear, cytosolic, and membrane-associated targets, enzymes, and epigenetic factors.

## Funding rounds

- Series B, Dec 12, 2022, $9.1M — SV Health Investors
- Series B, Oct 12, 2020, $36M — Novartis Venture Fund, Gilde Healthcare, Forbion, Eli Lilly & Company, BioMotiv, Advent Life Sciences
- Series A, Jun 28, 2019, $8.4M — European Investment Fund, BioMotiv, Advent Life Sciences, Scottish Investment Bank

## Investors

- European Investment Fund (https://capitalatlas.ai/funds/european-investment-fund) — Series A
- BioMotiv — Series A, Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B
- Scottish Investment Bank — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Eli Lilly & Company — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B